세계 면역글로불린 시장 규모 - 제품 유형별, 투여 경로별, 용도별, 최종 용도별 예측(2023-2032년)

Immunoglobulin market size is predicted to observe 7.7% CAGR during 2023 and 2032 owing to the escalating incidence of immunodeficiency disorders, including primary immunodeficiency diseases and secondary immunodeficiency diseases. According to a 2021 report by National Library of Medicine, more than 6 million people across the globe are affected by primary immunodeficiencies, of which nearly 70% to 90% are not diagnosed.

The expanding applications of immunoglobulin in treating various autoimmune and inflammatory diseases is bolstering market growth. The ongoing R&D activities in biotechnology are further contributing to the introduction of innovative immunoglobulin products, fostering a competitive market landscape.

The overall immunoglobulin industry is classified based on product type, route of administration, application, end-use, and region.

The IgA product type segment will garner massive revenues by 2032 as immunoglobulin A (IgA) is a key component of the immune system which provides essential defense against infections. IgA is effective in preventing infections in mucosal tissues such as the respiratory and gastrointestinal tracts. As research advances, IgA-based therapies will emerge as a promising avenue in the treatment of various diseases, further solidifying the significance of this segment.

The multifocal motor neuropathy (MMN) segment is anticipated to witness substantial growth through 2032. The rising prevalence of MMN, a rare neurological disorder characterized by muscle weakness and atrophy, is fueling the demand for immunoglobulin therapies. With ongoing clinical trials and research endeavors exploring the efficacy of immunoglobulins in managing MMN symptoms, this application segment is poised to be a lucrative avenue for the market.

Asia Pacific immunoglobulin market is expected to record strong CAGR from 2023 to 2032 owing to the increasing healthcare expenditure, rising prevalence of immunodeficiency disorders, and a growing aging population. Moreover, advancements in the healthcare infrastructure across the region and a surge in awareness regarding the benefits of immunoglobulin therapies are shaping the Asia Pacific industry dynamics.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 COVID-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Immunoglobulin industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Product type trends
  • 2.1.4 Route of administration trends
  • 2.1.5 Application trends
  • 2.1.6 End-use trends

Chapter 3 Immunoglobulin Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing geriatric population
    • 3.2.1.2 Increasing prevalence of immunodeficiency diseases
    • 3.2.1.3 Growing adoption of immunoglobulin
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of therapy
    • 3.2.2.2 Stringent government regulations
• 3.3 Growth potential analysis
  • 3.3.1 By product type
  • 3.3.2 By route of administration
  • 3.3.3 By application
  • 3.3.4 By end-use
• 3.4 COVID- 19 impact analysis
• 3.5 Route of administration comparison table
• 3.6 Regulatory landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Immunoglobulin Market Size and Forecast, By Product Type (USD Million)

• 5.1 Key trends, by product type
• 5.2 IgG
• 5.3 IgA
• 5.4 IgM
• 5.5 IgD
• 5.6 IgE

Chapter 6 Immunoglobulin Market Size and Forecast, By Route of Administration (USD Million)

• 6.1 Key trends, by route of administration
• 6.2 Intravenous (IVIG)
• 6.3 Subcutaneous (SCIg)

Chapter 7 Immunoglobulin Market Size and Forecast, By Application (USD Million)

• 7.1 Key trends, by application
• 7.2 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• 7.3 Multifocal motor neuropathy (MMN)
• 7.4 Primary immunodeficiency disease (PID)
• 7.5 Secondary immunodeficiency disease (SID)
• 7.6 Guillain-Barre syndrome
• 7.7 Immune thrombocytopenic purpura (ITP)
• 7.8 Other applications

Chapter 8 Immunoglobulin Market Size and Forecast, By End-use (USD Million)

• 8.1 Key trends, by end-use
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Homecare

Chapter 9 Immunoglobulin Market Size and Forecast, By Region (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Poland
  • 9.3.7 Switzerland
  • 9.3.8 Netherlands
  • 9.3.9 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Thailand
  • 9.4.7 Indonesia
  • 9.4.8 Vietnam
  • 9.4.9 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Columbia
  • 9.5.5 Chile
  • 9.5.6 Peru
  • 9.5.7 Rest of Latin America
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Israel
  • 9.6.5 Rest of MEA

Chapter 10 Company Profiles

• 10.1 Baxter international Inc.
• 10.2 Johnson & Johnson (Omrix Biopharmaceuticals Inc.)
• 10.3 Pfizer Inc.
• 10.4 Takeda Pharmaceutical Company Limited
• 10.5 Grifols SA
• 10.6 Kedrion S.p.A
• 10.7 CSL Behring
• 10.8 Biotest AG
• 10.9 Octapharma AG
• 10.10 ADMA Biologics, Inc.
• 10.11 Shanghai RAAS Blood Products Co. Ltd